Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cryofocus Medtech (Shanghai) Co. Ltd. Class H ( (HK:6922) ).
Cryofocus Medtech (Shanghai) Co., Ltd. has announced that its Board of Directors will meet on August 8, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend, which could impact the company’s financial strategy and shareholder returns.
More about Cryofocus Medtech (Shanghai) Co. Ltd. Class H
Cryofocus Medtech (Shanghai) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the medical technology industry. The company, along with its subsidiaries, operates in the healthcare sector, providing innovative medical solutions.
Average Trading Volume: 85,436
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.4B
For detailed information about 6922 stock, go to TipRanks’ Stock Analysis page.